Untitled

[akpharma]

Denosumab in India 2026: A Distributor’s Guide to Prolia, Xgeva, and Denorange

Denosumab has become one of the most widely supplied biologics in India for bone health management, spanning two very different clinical worlds — osteoporosis prevention and cancer-related bone protection. For hospitals, pharmacies, and procurement teams, the practical challenge is rarely about treatment decisions, which always rest with the prescribing physician — it is about sourcing the right product, in the right strength, with verified authenticity and proper cold chain handling. This guide looks at denosumab from that distributor’s perspective, helping procurement teams understand what they are ordering and why getting the product selection right matters.

Read More…

[akpharma]

How to Verify That Your Imported Cancer Medicine Is Genuine — A Safety Guide for Hospital Pharmacists in India 2026

In May 2026, Delhi Police busted a counterfeit medicine racket worth nearly Rs 10 crore — four people arrested for manufacturing and supplying fake life-saving drugs for cancer and liver disease. Fake medicines, packaging equipment, forged labels — all recovered from an operation supplying hospitals across multiple states.

Read More...

[akpharma]

Palbociclib, Ribociclib and Abemaciclib in India 2026 — Which CDK4/6 Inhibitor Is Right for Your Patient?

Breast cancer is now the most commonly diagnosed cancer among Indian women. Within that broad diagnosis, hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer accounts for approximately 60-70% of all cases — and for this large and clinically important group, the treatment landscape has been fundamentally transformed over the past decade by a class of medicines called CDK4/6 inhibitors.

Read More…

[akpharma]

Lutetium-177 PSMA Therapy for Prostate Cancer in India — Who Qualifies, How It Works, and Where to Access It in 2026

Hormone therapy, chemotherapy if the cancer advanced, and, more recently, oral targeted medications like Enzalutamide (Glenza) and Abiraterone (Abirapro) were the only treatments available to Indian men with advanced prostate cancer for the majority of the previous 20 years. These medications are truly effective, however many people only see results for a short period of time. The alternatives quickly become limited after castration resistance emerges and the cancer begins to thrive in spite of hormone suppression.

This is going to change in 2026 thanks to one of the most clinically significant developments in prostate cancer treatment in recent memory: radioligand therapy using Lutetium-177 PSMA, a precision treatment that uses targeted radiation to find and kill prostate cancer cells throughout the body while largely sparing surrounding healthy tissue.

This article describes Lu-177 PSMA therapy, what the most recent clinical data from 2026 indicates, who is eligible for it, and what Indian patients and oncologists should know about getting it.

Read More…

[akpharma]

Enhertu and the ADC Revolution — Why Antibody-Drug Conjugates Are the Most Important Development in Cancer Treatment in 2026

A novel cancer medication that most doctors were unaware of was authorized by the FDA in December 2019. With yearly sales of USD 3.75 billion, it was the world's best-selling antibody-drug conjugate by 2024. Leading oncologists referred to it as the most revolutionary cancer medication created in the previous ten years, and by early 2026 it had been granted Priority Review for yet another additional indication.

Enhertu (Trastuzumab Deruxtecan) is the medication. Antibody-drug conjugates, the underlying technology, are changing cancer treatment more quickly than any other advancement in oncology to yet.

Read More

[akpharma]

Ozempic vs Mounjaro vs Wegovy in India 2026 — Which GLP-1 Should Your Patient Choose?

In March 2026, the therapeutic landscape for obesity and diabetes in India underwent a significant shift. After Novo Nordisk's primary Indian patent for semaglutide expired on March 20, 2026, a number of Indian pharmaceutical companies quickly introduced their own versions at significantly reduced costs. In India, branded Ozempic costs between ₹8,800 and ₹11,175 per month, whereas the lowest generic is now ₹1,290. Within months of its introduction, Mounjaro emerged as India's best-selling medication by value, indicating a distinct trend in the country toward expensive chronic care medications. The three most talked-about GLP-1 medications in India at the moment, Ozempic, Mounjaro India, and Wegovy, are covered in this article along with their clinical differences, most recent prices, and trial data. Read More...

[akpharma]

How A.K. Pharma Ensures Genuine Medicine Supply Across India

The most crucial element when hospitals, clinics, and pharmacies search for a medication provider is confidence. In India, there is a significant problem with counterfeit or subpar medications, and selecting the incorrect supplier might endanger patients. We at A.K. Pharma are aware of this obligation. We have based our entire operation as a certified medicine wholesaler in Delhi on the tenet that all of the medications we provide must be 100% authentic.

Read More...